·73·中国现代药物应用2024年4月第18卷第7期ChinJModDrugAppl,Apr2024,Vol.18,No.7厄贝沙坦氢氯噻嗪片仿制药与原研药治疗轻中度原发性高血压的成本-效果比较汤雅惠肖基达【摘要】目的比较厄贝沙坦氢氯噻嗪片(商品名：倍悦)仿制药与厄贝沙坦氢氯噻嗪片(商品名：安博诺)原研药治疗轻中度原发性高血压的成本-效果(C/E)。方法选择88例新发轻中度高血压患者作为研究对象,采用随机数字表法分为仿制组和原研组,各44例。仿制组患者应用厄贝沙坦氢氯噻嗪片仿制药治疗,原研组患者应用厄贝沙坦氢氯噻嗪片原研药治疗。比较两组治疗效果、治疗前后血压变化、不良反应发生情况、治疗成本。结果仿制组的治疗总有效率95.45%与原研组的97.73%对比,差异无统计学意义(P>0.05)。治疗前后组内收缩压、舒张压对比差异显著(P<0.05),且治疗4、8周后两组收缩压、舒张压显著低于治疗前(P<0.05)；两组治疗前后组间的收缩压、舒张压对比,差异无统计学意义(P>0.05)。仿制组的药物不良反应发生率9.09%与原研组的6.82%对比,差异无统计学意义(P>0.05)。仿制组的直接成本(52.27±9.85)元、日均费用(0.93±0.18)元均低于原研组的(374.00±103.18)、(6.68±1.84)元(P<0.05)。仿制组的C/E为0.55,优于原研组的3.83。结论厄贝沙坦氢氯噻嗪片仿制药与原研药治疗轻中度高血压的整体疗效、安全性相当,但仿制药费用更低,更适合长期用药。【关键词】原发性高血压；厄贝沙坦氢氯噻嗪片；仿制药；原研药；成本-效果DOI：10.14164/j.cnki.cn11-5581/r.2024.07.018CosteffectivenesscomparisonofgenericirbesartanhydrochlorothiazidetabletsandoriginaldrugsinthetreatmentofmildtomoderateessentialhypertensionTANGYa-hui,XIAOJi-da.MediationDepartment,ZhongshanCityPeople'sHospital,Zhongshan528400,China【Abstract】ObjectiveTocomparethecosteffectiveness(C/E)comparisonofgenericirbesartanhydrochlorothiazidetablets(tradename:Beiyue)andoriginaldrugs(tradename:Ambonor)inthetreatmentofmildtomoderateessentialhypertension.MethodsAtotalof88casesofpatientswithnewlydiagnosedmildtomoderatehypertensionwereselectedasthestudysubjects.Thepatientsweredividedintothegenericgroupandtheoriginalgroupbyrandomnumbertablemethod,with44casesineachgroup.Thegenericgrouptookgenericirbesartanhydrochlorothiazidetabletsfortreatment,andtheoriginalgrouptookoriginaldrugsfo...
